CapTemY90 for Grade 2 NET Liver Metastases

Eligibility Criteria

• * Patients with confirmed diagnosis of histologic grade 2 neuroendocrine tumor with unresectable liver metastases (primary tumor or other extrahepatic disease may be present)
• * Patients with at least one measurable liver metastases, with size \> 1cm (RECIST criteria)
• * Patients with liver dominant disease defined as ≥50% tumor body burden confined to the liver
• * Liver tumor burden does not exceed 50% of the liver volume
• * Patent main portal vein
• * At least 4 weeks since last administration of last chemotherapy and /or radiotherapy
• * Age \>18 years.
• * Life expectancy of greater than 6 months.
• * ECOG performance status 0-2.
• * Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times ULN, albumin ≥2.5g/dl.
• * Patients must have adequate organ and marrow function as defined below:
• * platelets \>100,000/mcL (may be corrected by transfusion)
• * serum creatinine \< 2.0 mg/dl
• * INR \<1.6, (may be corrected by transfusion)
• * Ability to understand and the willingness to sign a written informed consent document.
• * Women of child bearing potential and fertile men are required to use effective contraception (negative urine or serum βHCG for women of child-bearing age)
• * Contraindications to capecitibine or temozolomide
• * Contraindicated for both contrast-enhanced MRI and CT
• * Patients previously treated with transarterial embolization (with or without chemotherapy) or with radioembolization (Y-90 microspheres)
• * Contraindication for radioembolization procedures:
• * excessive hepatopulmonary shunt as determined by the investigator
• * inability to deliver Y90 microspheres without risk of non-target embolization of extra-hepatic structures
• * Subjects consenting to the trial who fail their simulation angiography will be removed from the study and replaced.
• * Patients may not be receiving any other investigational agents.
• * Absolute contraindication to intravenous iodinated contrast (Hx of significant previous contrast reaction, not mitigated by appropriate pre-medication).
• * Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal papilla;
• * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• * Pregnant and lactating women are ineligible